Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. Revised Protocol No.: 04 Date: 31-May-2019 192 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS APPENDIX 6 MANAGEMENT ALGORITHMS FOR IMMUNO-ONCOLOGY AGENTS These general guidelines constitute guidance to the investigator and may be supplemented by discussions with the medical monitor representing the Sponsor. The guidance applies to all immuno-oncology (I-O) agents and regimens.